REVVITY, INC.
Financial highlights
| Metric | FY 12/28/25 | FY 12/29/24 | FY 12/31/23 | FY 01/01/23 | FY 01/02/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.9 | $2.8 | $2.8 | $3.3 | $3.8 |
| Operating income | $0.4 | $0.3 | $0.3 | $0.7 | $1.3 |
| Net income | $0.2 | $0.3 | $0.7 | $0.6 | $0.9 |
| Balance Sheet | |||||
| Total debt | $3.2 | $3.2 | $3.9 | $4.4 | $5.0 |
| Cash Flow Statement | |||||
| Free cash flow | $0.5 | $0.5 | $<0.1 | $0.6 | $1.3 |
| Dividends | $<0.1 | $<0.1 | $<0.1 | $<0.1 | $<0.1 |
| Share repurchases | $0.8 | $0.4 | $0.4 | $0.1 | $0.1 |
Shares outstanding 111.6M · Free float 99.5%
Annual filing data through FY ended December 28, 2025; float as of September 15, 2026.
Earnings
Other Coverage
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 21, 2026
Filing Trends
Supreme Court IEEPA Tariff Ruling Opens Refund Path for Importers
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
August 4, 2026
Deals
Revvity to Divest China Immunodiagnostics Business